Anticoccidial composition containing quinic acid and its use

Abstract

The present application relates to compositions for preventing, ameliorating or treating coccidiosis and antiprotozoal compositions against Eimeria protozoa, which contain quinic acid.

Description

[Technical Field]

[0001] [CROSS-REFERENCE TO RELATED APPLICATIONS] This application claims the benefit of priority based on Korean Patent Application No. 10-2023-0103638 dated August 8, 2023, and all contents disclosed in the documents of this Korean patent application are incorporated herein by reference.

[0002] The present application relates to the anticoxidial use of quinic acid and / or its salts. [Background technology]

[0003] Coccidiosis is an intestinal disease caused by Eimeria, a protozoan parasite belonging to the phylum apicomplexan. Infection with coccidiosis causes symptoms such as digestive disorders, diarrhea, and weight loss, and can even lead to the death of livestock, causing a significant economic impact on farmers worldwide (Williams RB. A compartmentalized model for the estimation of the cost of coccidiosis to the world's chicken production industry. Int J Parasitol. 1999; 29(8):1209-1229).

[0004] In recent years, many researchers have developed anticoccidial agents, such as ionophores or chemically synthetic compounds, that can inhibit the formation of oocyst cell walls or the asexual and sexual reproduction of the protozoan as therapeutic agents for the treatment of coccidiosis. However, side effects have occurred, such as the emergence of drug-resistant protozoan due to the long-term use of a shuttle program that alternates between ionophores and chemically synthetic compounds.

[0005] In particular, antibiotics accumulated in animals due to misuse and overuse have become a serious problem when they are ingested by humans through meat, and countries around the world are moving toward banning the administration of antibiotics due to the problem of antibiotic residues in livestock products. Therefore, there is an urgent need for research and development into alternatives to existing anticoccidial agents, which have side effects such as the emergence of drug-resistant strains and problems with their retention in the body. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] U.S. Patent Publication US2003-0091589A1 (published May 15, 2003) Summary of the Invention [Problem to be solved by the invention]

[0007] The object of the present application is to provide the use of quinic acid and / or its salts for the prevention, amelioration, and / or treatment of coccidiosis.

[0008] Another object of the present application is to provide a feed composition for preventing or ameliorating coccidiosis, which comprises quinic acid and / or its salts.

[0009] Another object of the present application is to provide a pharmaceutical composition for preventing or treating coccidiosis, which comprises quinic acid and / or a salt thereof.

[0010] Another object of the present application is to provide a use of quinic acid and / or a salt thereof for producing a composition (feed composition, pharmaceutical composition) for preventing, ameliorating, and / or treating coccidiosis.

[0011] It is still another object of the present application to provide a method for preventing, ameliorating, and / or treating coccidiosis, comprising the step of administering quinic acid and / or a salt thereof to a subject in need thereof. The method may further comprise the step of identifying the subject in need of prevention, amelioration, and / or treatment of coccidiosis prior to the administering step.

[0012] Yet another object of the present application is to provide an antiprotozoal use of quinic acid and / or its salts against protozoan parasites of the genus Eimeria.

[0013] It is still another object of the present application to provide an antiprotozoal composition against Eimeria protozoa, which comprises quinic acid and / or a salt thereof.

[0014] Yet another object of the present application is to provide use of quinic acid and / or a salt thereof for producing an antiprotozoal composition against protozoan parasites of the genus Eimeria.

[0015] It is still another object of the present application to provide a method for controlling Eimeria protozoa, which comprises the step of administering quinic acid and / or a salt thereof to a subject in need of control of Eimeria protozoa. [Means for solving the problem]

[0016] This will be explained in detail below. Meanwhile, each description and embodiment disclosed in this application may also be applied to each other description and embodiment. In other words, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, the specific descriptions provided below should not be construed as limiting the scope of this application. Furthermore, those skilled in the art will recognize or ascertain, using no more than routine experimentation, numerous equivalents to the specific aspects of this application described herein. Furthermore, such equivalents are intended to be encompassed by this application.

[0017] The present application will now be described in more detail.

[0018] One aspect provides a composition for preventing, ameliorating, and / or treating coccidiosis comprising quinic acid and / or a salt thereof.

[0019] Another aspect provides the use of quinic acid and / or a salt thereof for the manufacture of a composition for the prevention, amelioration and / or treatment of coccidiosis.

[0020] Another aspect provides a method for preventing, ameliorating, and / or treating coccidiosis, comprising administering quinic acid and / or a salt thereof to a subject in need thereof. The method may further comprise, prior to the administering step, identifying the subject in need of coccidiosis prevention, amelioration, and / or treatment. In one example, identifying the subject may comprise detecting oocysts of a protozoan capable of inducing coxidium from feces isolated from the subject.

[0021] The composition for preventing, ameliorating, and / or treating coccidiosis may be a feed composition or a pharmaceutical composition.

[0022] In the present application, quinic acid may be a compound having the structure of the following chemical formula 1 (CH 12 O 6, Cas No. 77-95-2, PubChem CID NO. 6508). [ka]

[0023] The quinic acid or a salt thereof may be purchased commercially, extracted and separated from natural products or bacterial strains, or prepared by a conventional organic synthesis method, but is not limited thereto.

[0024] As used herein, the term "quinic acid salt" refers to a physiologically acceptable salt among salts in which a cation and anion are bound by electrostatic attraction, such as a salt acceptable for use in feed compositions, a pharmaceutically acceptable salt, and / or a salt acceptable for use in antiprotozoan compositions. For example, the salt may be one or more selected from the group consisting of metal salts, salts with organic bases, salts with inorganic acids, salts with organic acids, and salts with basic or acidic amino acids. In one example, the metal salt may be one or more selected from the group consisting of alkali metal salts (sodium salts, potassium salts, etc.), alkaline earth metal salts (calcium salts, magnesium salts, barium salts, etc.), aluminum salts, etc.; the salt with an organic base may be one or more selected from the group consisting of salts with triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N,N-dibenzylethylenediamine, etc.; the salt with an inorganic acid may be one or more selected from the group consisting of salts with hydrochloric acid, hydrobromic acid, nitric acid, etc. The salt with an organic acid may be one or more selected from the group consisting of salts with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc.; the salt with a basic amino acid may be one or more selected from the group consisting of salts with arginine, lysine, ornithine, etc.; and the salt with an acidic amino acid may be one or more selected from the group consisting of salts with aspartic acid, glutamic acid, etc.

[0025] In the present application, those having excellent anticoxidial efficacy (activity, effect) may mean one or more (e.g., one or more, two or more, three or more, or all four) selected from the group consisting of 1 to 4 below: (1) The anticoccidial index (ACI) was higher than that of the control group; (2) administered to animals in which coccidiosis has been induced to reduce mortality, lesion scores (e.g., cecal lesion scores), and / or fecal oocyst production compared to controls; (3) inhibiting coccidiosis-induced weight loss; and (4) It has higher insecticidal activity against protozoa that cause coccidiosis compared to the control group.

[0026] In the present application, the control group may refer to a negative control group (a group that is not treated with any agent or a group that is treated with water and / or a buffer) and / or a positive control group that includes an existing known anticoxidial agent (e.g., diclazuril and / or salinomycin).

[0027] The composition according to one example may have one or more properties (e.g., one or more, two or more, three or more, four or more, five or more, or all six) selected from the group consisting of the following (1) to (6), and the properties may be superior to those of a control group: (1) Excellent anticoxidial activity; (2) Excellent antiprotozoal activity against protozoa that cause coccidiosis; (3) Excellent acid resistance; (4) Excellent heat resistance; (5) Excellent in vivo stability and / or safety; and (6) Excellent effect on improving weight gain.

[0028] An example composition can be administered to the body and maintain excellent anticoxidial activity for a long period of time, has excellent in vivo stability, can maintain excellent anticoxidial activity in environments with various temperature and / or pH ranges, can be applied to various products (e.g., feed additives), and has excellent storage stability.

[0029] In one example, the composition is not absorbed by tissues and organs other than the intestine (e.g., blood, liver, kidneys, and / or spleen) when administered to the body, resulting in low residual amounts in the body and excellent in vivo safety.

[0030] In one example, an excellent effect of improving weight gain may mean an excellent effect of increasing the weight of an individual when administered to the individual, and in one example, the weight gain may mean the weight gain per day, and the individual may be an individual in which coccidiosis has been induced.

[0031] The composition according to one embodiment exhibits anticoxidial activity equal to or greater than that of existing known anticoxidial agents, but does not induce side effects or drug resistance, and is therefore safe for long-term use.

[0032] In this application, "prevention" refers to any action that suppresses or delays the onset of a disease by administering a composition according to an embodiment, "treatment" refers to any action that improves or favorably changes the symptoms of an individual suspected of or affected by a disease by administering a composition according to an embodiment, and "amelioration" refers to any action that at least reduces a parameter associated with the state of the disease being treated, for example, the severity of symptoms, by administering a composition according to an embodiment. The disease may be coccidiosis.

[0033] In this application, "coccidiosis" refers to a disease caused by coccidia protozoa (protozoa capable of inducing coccidiosis, such as Eimeria coccidia) that parasitize the cytoplasm of the submucosa in the gastrointestinal epithelium, destroying the epithelium and causing enteritis. It is a protozoal disease that causes economic damage to poultry farms by causing loose stools, diarrhea, and bloody stools, resulting in a decrease in weight gain and an extension of the shipping age. Coccidiosis can occur not only in poultry but also in birds and mammals. Specifically, coccidiosis can infect cattle, rabbits, goats, dogs, cats, and laboratory animals such as mice and rats, and can be particularly fatal to poultry such as chickens. In one example, coccidiosis can include acute coccidiosis, subacute coccidiosis, and chronic coccidiosis. Acute coccidiosis may manifest as bloody stools, loss of energy, and anemia within 48 hours of infection, and may result in the death of infected individuals; subacute coccidiosis may manifest as bloody diarrhea and / or anemia after infection; and chronic coccidiosis may manifest as loose stools and / or weight loss after diarrhea for 1 to 2 days after infection.

[0034] When oocysts (cysts, parasite eggs) of Coxidium species mature into sporulated oocysts under high humidity and temperature conditions, they become infectious. After undergoing a certain life cycle within the individual's body, the oocysts are easily transmitted when excreted in feces, and the oocyst life cycle is repeated. Coxidium oocysts (cysts) are known to be highly resistant to the external environment, with the cyst wall consisting of two layers, an inner and outer. The outer layer of the cyst wall is made of a gelatinous substance that is highly resistant to physical external pressure, while the inner layer is rich in nucleoprotein and is highly resistant to chemicals, such as disinfectants. Oocysts of Coxidium protozoa species can contain four sporocysts, each of which can contain two sporozoites. After infecting an animal in the form of oocysts, the sporangia and sporozoites are released and multiply intracellularly. After sexual and / or asexual reproduction, the sporozoites form oocysts and can be excreted in feces. In one example, the term "sporozoite" can be used interchangeably with "protozoa," and the sporozoites (protozoa) can cause lesions.

[0035] By way of example, the coccidiosis may be induced by the protozoan Eimeria sp. In one example, the Eimeria protozoa is Eimeria acervulina (gizzard coccosporozoa), Eimeria tenella (chicken cecal coccosporozoa), Eimeria maxima (maxima coccosporozoa), Eimeria necatrix (Eimeria necatrix coccosporozoa), Eimeria brunetti (Eimeria brunetti) (Eimeria hagani) (Eimeria hagani) (Eimeria mitis) (Eimeria mitis) (Eimeria praecox) (Eimeria mivati) (Eimeria aurachi) (Eimeria aurati, Eimeria baueri, Eimeria lepidosirenis, Eimeria leucisci, Eimeria rutile, Eimeria vanasi, Eimeria amphisbaeniarum, Eimeria witchery, Eimeria yemenensae, Eimeria adenoeides, Eimeria colchici, Eimeria curvata, Eimeria dispersa, Eimeria duodenalis duodenalis, Eimeria fraterculae, Eimeria gallopavonis, Eimeria innocua, Eimeria meleagridis, Eimeria meleagrimitismeleagrimitis, Eimeria phasiani, Eimeria procera, Eimeria purpureicephali, Eimeria ahsata, Eimeria alabamensis, Eimeria alijevi, Eimeria aspheronica, Eimeria arloingi, Eimeria arundeli, Eimeria bakuensis, Eimeria bovis, Eimeria cameli, Eimeria caprina, Eimeria caprobina caprovina, Eimeria christenseni, Eimeria clethrionomyis, Eimeria coecicola, Eimeria contorta, Eimeria couesii, Eimeria crandallis, Eimeria dammahensis, Eimeria dowleri, Eimeria exigua, Eimeria falciformis, Eimeria farasanii, Eimeria ferrisi, Eimeria flavescens flavescens, Eimeria gallatii, Eimeria granulosa, Eimeria hirci, Eimeria intestinalisintestinalis, Eimeria irresidua, Eimeria intricata, Eimeria jolchijevi, Eimeria krijgsmanni, Eimeria larimerensis, Eimeria macusaniensis, Eimeria magna, Eimeria marconii, Eimeria media, Eimeria melanuri, Eimeria myoxi, Eimeria nagpurensis, Eimeria nyszulji nieschulzi, Eimeria ninakohlyakimovae, Eimeria ovinoidalis, Eimeria pallida, Eimeria palustris, Eimeria papillata, Eimeria perforans, Eimeria phocae, Eimeria pileata, Eimeria pipistrellus, Eimeria piriformis, Eimeria prionotemni, Eimeria procyonis, Eimeria punctata punctate), Eimeria roobroucki, Eimeria saudiensis, Eimeria sealanderi, Eimeria separata, Eimeria stydaeThe fungus may be one or more species selected from the group consisting of Eimeria stiedae, Eimeria ursini, Eimeria vermiformis, Eimeria weybridgensis, Eimeria wobati, and Eimeria zuernii.

[0036] In one example, the composition may be effective in preventing, ameliorating, and / or treating coccidiosis induced by one or more protozoa selected from the group consisting of Eimeria protozoa listed in Table 1 below, and the Eimeria protozoa listed in Table 1 below may each induce coccidiosis in the animals listed in Table 1.

[0037] [Table 1] TIFF2026507591000004.tif208149 TIFF2026507591000005.tif203149 TIFF2026507591000006.tif214149 TIFF2026507591000007.tif209149 TIFF2026507591000008.tif134149

[0038] An example composition may be highly effective in preventing, ameliorating, and / or treating coccidiosis induced by Eimeria tenella.

[0039] In one example, the prevention or amelioration of coccidiosis may mean one or more (e.g., one or more, two or more, three or more, or all four) types selected from the group consisting of the following (1) to (4), and may be, for example, a reduction, inhibition, and / or increase in one or more (e.g., one or more, two or more, or all three) types selected from the group consisting of the following (1) to (3) compared to a control group (a negative control group and / or a positive control group): (1) A decrease in one or more of the following: lesion score (e.g., cecal lesion score), fecal oocyst excretion, and mortality rate; (2) suppression of weight loss due to coccidiosis; and (3) The anticoccidial index (ACI) increased.

[0040] In one example, the lesion scoring method for determining the lesion score can be performed with reference to Johnson JK & Reid WM (1970) (Joyce Johnson, W. Malcolm Reid, Anticoccidial drugs: Lesion scoring techniques in battery and floor-pen experiments with chickens, Experimental parasitology, 1970), and the lesion score can be on a scale of 0 to 4. In one example, the lesion score can refer to the lesion scores measured in the cecum, duodenum, and / or jejunum, and can be calculated as the sum of the respective lesion scores measured in each organ (cecum, duodenum, and / or jejunum).

[0041] In one example, the fecal oocyst output can be measured by collecting feces excreted from an individual and measuring the feces using a microscope or a counting chamber (e.g., a McMaster chamber).

[0042] In one example, the mortality rate may refer to the mortality rate of animals in which coccidiosis has been induced, and the number of animals that died from causes other than coccidiosis after a post-mortem examination may be excluded.

[0043] In one example, individuals in which coccidiosis has been induced may lose more weight than individuals in which coccidiosis has not been induced, and a composition according to one example may inhibit weight loss due to coccidiosis induction.

[0044] In one example, the anticoxidial comprehensive index can be calculated by the following Equation 1, and the lesion score in Equation 1 can be calculated as described above. (Equation 1) Anticoccidial Comprehensive Index (ACI) = (post-challenge survival rate (%)) + (daily weight gain (%) relative to the negative control group) - (lesion score x 10) - (fecal oocyst excretion index).

[0045] The challenge inoculation may refer to administration of a protozoan capable of inducing coccidiosis (e.g., oral inoculation). In one example, the survival rate may be measured 5 to 10 days, 7 to 10 days, 8 to 10 days, 7 to 9 days, 7 to 8 days, or 7 days after the challenge inoculation, and the survival rate may be measured by excluding the number of individuals that died from causes other than coccidiosis through a post-mortem examination.

[0046] In Equation 1, the weight gain relative to the negative control group may be a value calculated as a percentage based on the value of the negative control group (e.g., a negative control group not infected with the protozoan).

[0047] The lesion score in the above formula 1 is as described above.

[0048] In Equation 1, the fecal oocyst excretion index is calculated as a percentage based on the value of a negative control group (e.g., a negative control group infected with protozoa), and the calculated result may be expressed as 0 if the level is between 0% and less than 1%, 5 if the level is between 1% and less than 26%, 10 if the level is between 26% and less than 51%, 20 if the level is between 51% and less than 76%, and 40 if the level is between 76% and less than 100%.

[0049] In one example, the active ingredient (quinic acid or a salt thereof) is present in the feed composition at 2 w / w% or less, 1 w / w% or less, less than 1 w / w%, 10 -1 w / w% or less, 5×10 -2 w / w% or less, 2.5×10 -2 Less than w / w%, 2×10 -2 w / w% or less, 1.25×10 -2 w / w% or less, 10 -2 w / w% or less, 9×10 -3 w / w% or less, 8×10 -3 w / w% or less, 7×10 -3 w / w% or less, 6×10 -3 w / w% or less, 5×10 -3 w / w% or less, 4×10 -3 w / w% or less, 10 -7 w / w% or more, 10 -6 w / w% or more, 10 -5 w / w% or more, 10 -4 w / w% or more, 5×10 -4 w / w% or more, 10 -3 w / w% or more, 1.5 x 10 -3 w / w% or more, 2×10 -3 w / w% or more, 3×10 -3 w / w% or more, 4×10 -3 w / w% or more, 5×10 -3 w / w% or more, 10 -7 ~1w / w%, 10 -7 ~10 -1 w / w%, 10 -7 ~5×10 -2 w / w%, 10 -7 ~10 -2 w / w%, 10 -7 ~5×10 -3 w / w%, 10 -7~4×10 -3 w / w%、10 -7 ~10 -3 w / w%、10 -7 ~5×10 -4 w / w%、10 -7 ~10 -4 w / w%、10 -7 ~10 -5 w / w%、10 -6 ~1w / w%、10 -6 ~10 -1 w / w%、10 -6 ~5×10 -2 w / w%、10 -6 ~10 -2 w / w%、10 -6 ~5×10 -3 w / w%、10 -6 ~4×10 -3 w / w%、10 -6 ~10 -3 w / w%、10 -6 ~5×10 -4 w / w%、10 -6 ~10 -4 w / w%、10 -6 ~10 -5 w / w%、10 -5 ~1w / w%、10 -5 ~10 -1 w / w%、10 -5 ~5×10 -2 w / w%、10 -5 ~10 -2 w / w%、10 -5 ~5×10 -3 w / w%、10 -5 ~4×10 -3 w / w%、10 -5 ~10 -3 w / w%、10 -5 ~5×10 -4 w / w%、10 -5 ~10 -4 w / w%、10 -4 ~1w / w%、10 -4 ~10 -1 w / w%、10 -4 ~5×10 -2 w / w%、10 -4 ~10 -2 w / w%、10 -4 ~5×10-3 w / w%, 10 -4 ~4×10 -3 w / w%, 10 -4 ~10 -3 w / w%, 10 -4 ~5×10 -4 w / w%, 10 -3 ~1w / w%, 10 -3 ~10 -1 w / w%, 10 -3 ~5×10 -2 w / w%, 10 -3 ~10 -2 w / w%, 10 -3 ~5×10 -3 w / w%, 10 -3 ~4×10 -3 w / w%, 10 -3 ~2×10 -3 w / w%, or 10 -3 ~1.5×10 -3 In one example, the feed composition may be a feed (e.g., a compound feed and / or a plain feed that is ultimately ingested by an animal) containing the active ingredient in the above range based on the total weight.

[0050] In one example, the active ingredient (quinic acid or a salt thereof) is present in the feed composition at 10,000 ppm or less, 5,000 ppm or less, 2,000 ppm or less, 1,000 ppm or less, 500 ppm or less, 400 ppm or less, 300 ppm or less, 250 ppm or less, 200 ppm or less, 125 ppm or less, less than 125 ppm, 100 ppm or less, 90 ppm or less, 80 ppm or less, 70 ppm or less, 65 ppm or less, 0.001 ppm or more, 0.01 ppm or more, 0.1 ppm or more, 1 ppm or more, 5 ppm or more, 10 ppm or more, 15 ppm or more, 20 ppm or more, 30ppm or more, 40ppm or more, 50ppm or more, 0.001 to 2000ppm, 0.001 to 1500ppm, 0.001 to 1000ppm, 0.001 to 500ppm, 0.001 to 300ppm, 0.001 to 200ppm, 0.001 to 125ppm, 0.001 to 100ppm, 0.001 to 90ppm, 0.001 to 80ppm, 0.001 to 70ppm, 0.001 to 60ppm, 0.001 to 50ppm, 0.001 to 40ppm, 0.001 to 30ppm, 0.003 to 2000ppm, 0.003 to 1500ppm, 0. 003~1000ppm, 0.003~500ppm, 0.003~300ppm, 0.003~200ppm, 0.003~125ppm, 0.003~100ppm, 0.003~90ppm, 0.003~80ppm, 0.003~70ppm, 0.003~60p pm, 0.003~50ppm, 0.003~40ppm, 0.003~30ppm, 0.01~2000ppm, 0.01~1500ppm, 0.01~1000ppm, 0.01~500ppm, 0.01~300ppm, 0.01~200ppm, 0.01~125p pm, 0.01~100ppm, 0.01~90ppm, 0.01~80ppm, 0.01~70ppm, 0.01~60ppm, 0.01~50ppm, 0.01~40ppm, 0.01~30ppm, 0.1~2000ppm, 0.1~1500ppm, 0.1~10 00ppm, 0.1~500ppm, 0.1~300ppm, 0.1~200ppm, 0.1~125ppm, 0.1~100ppm, 0.1~90ppm, 0.1~80ppm, 0.1~70ppm, 0.1~60ppm, 0.1~50ppm, 0.1~40ppm, 0.1~30ppm, 1~2000ppm, 1~1500ppm, 1~1000ppm, 1~500ppm, 1~300ppm, 1~200ppm, 1~12 5ppm, 1~100ppm, 1~90ppm, 1~80ppm, 1~70ppm, 1~60ppm, 1~50ppm, 1~40ppm, 1~30ppm, 3~2000ppm, 3~1500ppm, 3~1000ppm, 3~500ppm, 3~300ppm, 3~200ppm, 3~125ppm, 3~10 0ppm, 3~90ppm, 3~80ppm, 3~70ppm, 3~60ppm, 3~50ppm, 3~40ppm, 3~30ppm, 5~2000ppm , 5 to 1500 ppm, 5 to 1000 ppm, 5 to 500 ppm, 5 to 300 ppm, 5 to 200 ppm, 5 to 125 ppm, 5 to 100 ppm, 5 to 90 ppm, 5 to 80 ppm, 5 to 70 ppm, 5 to 60 ppm, 5 to 50 ppm, 5 to 40 ppm, 5 to 30 ppm, 10 to 2000 ppm, 10 to 1500 ppm, 10 to 1000 ppm, 10 to 500 ppm, 10 to 300 ppm, 10 to 200 ppm, 10 to 125 ppm, 10 to 100 ppm, 10 to 90 ppm, 10 to 80 ppm, 10 to 70 ppm, 10 to 60 ppm, 10 to 50 ppm, 10 to 40 ppm or 10 to 30 ppm. .

[0051] In one example, when the active ingredient is contained within the above range, the anticoxidial activity may be more excellent.

[0052] In this application, "feed" can refer to any natural or artificial formula, meal, etc., or components of said meal, intended or suitable for eating, ingesting, and digestion by an animal. An example feed composition can additionally include a concentrate and / or a specialized feed. The concentrated feed may be animal feed such as seeds and fruits including grains such as wheat, oats, and corn; brans including rice bran, wheat bran, and barley bran as by-products obtained by refining grains; oil cakes which are by-products obtained by extracting oil from beans, rapeseed, sesame, flaxseed, coconut, etc.; residual starches which are the main component of starch cakes which are the remainder after starch is removed from sweet potatoes, potatoes, etc.; fish meal, fish meal, fish soluble which is a concentrated fresh liquid obtained from fish; meat meal, blood meal, feather meal, skim milk powder, dried whey which is the residual liquid obtained by drying whey which is the residual liquid when producing cheese from milk or casein from skim milk; yeast, chlorella, and / or seaweed.

[0053] The term "feed composition" as used herein refers to a form of feed ultimately ingested by animals, a dietary supplement that can be incorporated into feed, and / or a feed additive. The term "dietary supplement" refers to, for example, a formulation-containing composition that provides a therapeutic agent or digestive aid to animals. It is not typically a source of calorie intake, i.e., energy, but is ingested in addition to regular animal feed. The term "feed additive" refers to a substance added to feed for various purposes, such as supplementing nutrients and preventing weight loss, increasing the digestibility of fiber in feed, improving milk quality, preventing reproductive disorders and improving conception rates, and preventing high-temperature stress in summer. For example, the term "feed additive" refers to a substance added to feed for the purpose of preventing, ameliorating, or treating coccidiosis.

[0054] In one example, the feed composition may be a feed additive, and when the feed additive according to one example is blended into feed (e.g., compound feed and / or plain feed that is ultimately ingested by an animal), the amount of the feed additive may be 0.001% (w / w) or more, 0.005% (w / w) or more, 0.01% (w / w) or more, 0.05% (w / w) or more, 0.1% (w / w) or more, based on the total weight of the feed. w) or more, 0.5% (w / w) or more, 1% (w / w) or less, 0.5% (w / w) or less, 0.1% (w / w) or less, 0.05% (w / w) or less, 0.01% (w / w) or less, 0 .005%(w / w) or less, 0.001~1%(w / w), 0.001~0.5%(w / w), 0.001~0.1%(w / w), 0.001~0.05%(w / w), 0.0 01~0.01%(w / w), 0.001~0.005%(w / w), 0.005~1%(w / w), 0.005~0.5%(w / w), 0.005~0.1%(w / w), 0.005~0.05%(w / w), 0.005~0.01%(w / w), 0.01~1%(w / w), 0.01~0.5%(w / w), 0.01~0.1%(w / w), 0. It may be added at a weight amount of 0.1-0.05% (w / w), 0.05-1% (w / w), 0.05-0.5% (w / w), 0.05-0.1% (w / w), 0.1-1% (w / w), 0.1-0.5% (w / w), or 0.5-1% (w / w) and may be blended with feed ingredients, supplementary feed, adjuvants, and / or other types of additives other than the active ingredient(s) given as examples.

[0055] The feed composition may further contain any suitable excipient or solvent, such as water, that is commonly used in feed compositions, and such excipients may be, for example, preservatives, wetting agents, dispersing agents, suspending agents, buffers, stabilizers, or isotonicity agents, but are not limited thereto.

[0056] The pharmaceutical composition according to one embodiment may be used as a single agent, or may be prepared as a combined preparation by additionally including a pharmaceutical composition known to have an approved preventive or therapeutic effect against coccidiosis. A pharmaceutically acceptable carrier, excipient, or diluent may be added to the combined preparation to form a pharmaceutical unit dosage form.

[0057] In this application, "pharmaceutically acceptable" means that it does not significantly stimulate the living body and does not inhibit the biological activity and properties of the administered active substance. For example, the pharmaceutical composition containing a pharmaceutically acceptable carrier may have any one dosage form selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid contents, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories.

[0058] The pharmaceutical composition may be in various oral or parenteral dosage forms, and may be prepared using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, etc.

[0059] Solid formulations for oral administration include tablets, pills, powders, granules, capsules, etc., and can be prepared by mixing one or more compounds with at least one or more excipients, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc can also be used. Liquid formulations for oral administration include suspensions, liquid preparations, emulsions, syrups, etc., and can contain various excipients, such as wetting agents, sweeteners, flavoring agents, preservatives, etc., in addition to commonly used simple diluents such as water and liquid paraffin.

[0060] Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases may include witepsol, macrogol, Tween 61, cocoa butter, laurin butter, and glycerogelatin.

[0061] In one example, the pharmaceutical composition can be formulated into various forms, such as oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, and injections of sterile injection solutions, by a conventional method according to the intended purpose, and can be administered orally or via various routes, including intravenous, intraperitoneal, subcutaneous, rectal, and topical administration.

[0062] In one example, the pharmaceutical composition may further include a carrier, excipient, or diluent, and suitable examples of the carrier, excipient, or diluent that may be included include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, amorphous cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. The pharmaceutical composition may also include a filler, an anti-agglomerating agent, a lubricant, a wetting agent, a flavoring, an emulsifier, a preservative, etc.

[0063] For example, the effective amount of the active ingredient (quinic acid or a salt thereof) in the pharmaceutical composition varies depending on the age, sex, and weight of the patient (individual), but is generally 0.0001-1 mg / kg, 0.0001-0.1 mg / kg, 0.0001-0.01 mg / kg, 0.0001-0.001 mg / kg, 0.001-1 mg / kg, 0.001-0.1 mg / kg, 0.001-0.01 mg / kg, 0.01-1 mg / kg, 0.01-0.1 mg / kg, or 0.1-1 mg / kg per kg of body weight, administered daily or every other day, or in divided doses 1-3 times daily. However, the dosage may increase or decrease depending on the route of administration, severity of the disease, sex, weight, age, etc., and therefore, the scope of the present invention is not limited in any way to the above dosage amounts. In one example, when the composition is administered intraperitoneally, it may be administered at a concentration of 0.001 to 1 mg / kg.

[0064] In one example, the dosage of the pharmaceutical composition may vary depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, severity of disease, and the like.

[0065] In one example, the quinic acid or a pharmaceutically acceptable salt thereof is present in the pharmaceutical composition at 2 wt.% or less, 1 wt.% or less, less than 1 wt.% or less, 10 wt.% or less, -1 w / w% or less, 5×10 -2 w / w% or less, 2.5×10 -2 Less than w / w%, 2×10 -2 w / w% or less, 1.25×10 -2 w / w% or less, 10 -2 w / w% or less, 9×10 -3 w / w% or less, 8×10 -3 w / w% or less, 7×10 -3 w / w% or less, 6×10 -3 w / w% or less, 5×10 -3 w / w% or less, 4×10 -3 w / w% or less, 10 -7 w / w% or more, 10 -6 w / w% or more, 10 -5 w / w% or more, 10 -4 w / w% or more, 5×10 -4 w / w% or more, 10 -3 w / w% or more, 1.5 x 10 -3 w / w% or more, 2×10 -3 w / w% or more, 3×10 -3 w / w% or more, 4×10 -3 w / w% or more, 5×10 -3 w / w% or more, 10 -7 ~1w / w%, 10 -7 ~10 -1 w / w%, 10 -7 ~5×10 -2 w / w%, 10 -7 ~10 -2 w / w%, 10 -7 ~5×10 -3 w / w%, 10 -7 ~4×10 -3 w / w%, 10 -7 ~10 -3 w / w%, 10 -7 ~5×10 -4w / w%、10 -7 ~10 -4 w / w%、10 -7 ~10 -5 w / w%、10 -6 ~1w / w%、10 -6 ~10 -1 w / w%、10 -6 ~5×10 -2 w / w%、10 -6 ~10 -2 w / w%、10 -6 ~5×10 -3 w / w%、10 -6 ~4×10 -3 w / w%、10 -6 ~10 -3 w / w%、10 -6 ~5×10 -4 w / w%、10 -6 ~10 -4 w / w%、10 -6 ~10 -5 w / w%、10 -5 ~1w / w%、10 -5 ~10 -1 w / w%、10 -5 ~5×10 -2 w / w%、10 -5 ~10 -2 w / w%、10 -5 ~5×10 -3 w / w%、10 -5 ~4×10 -3 w / w%、10 -5 ~10 -3 w / w%、10 -5 ~5×10 -4 w / w%、10 -5 ~10 -4 w / w%、10 -4 ~1w / w%、10 -4 ~10 -1 w / w%、10 -4 ~5×10 -2 w / w%、10 -4 ~10 -2 w / w%、10 -4 ~5×10 -3 w / w%、10 -4 ~4×10 -3 w / w%、10 -4 ~10 -3 w / w%、10-4 ~5×10 -4 w / w%, 10 -3 ~1w / w%, 10 -3 ~10 -1 w / w%, 10 -3 ~5×10 -2 w / w%, 10 -3 ~10 -2 w / w%, 10 -3 ~5×10 -3 w / w%, 10 -3 ~4×10 -3 w / w%, 10 -3 ~2×10 -3 w / w%, or 10 -3 ~1.5×10 -3 It may be included at w / w%.

[0066] According to one example, the composition can be administered in a pharmaceutically effective amount. In this application, a "pharmaceutically effective amount" refers to an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to any medical treatment. The effective dose level can be determined based on factors including the type and severity of the patient's disease, the activity of the drug, sensitivity to the drug, the time of administration, the route of administration and excretion rate, the duration of treatment, concurrently used drugs, and other factors well known in the medical field. According to one example, the composition can be administered as an individual therapeutic agent or in combination with other anticoccidial agents. It can be administered simultaneously, separately, or sequentially with conventional therapeutic agents, and can be administered singly or multiple times. Taking all of the above factors into consideration, it is important to administer an amount that provides maximum efficacy at the minimum dose without side effects, which can be easily determined by one skilled in the art.

[0067] In one example, the quinic acid or a pharmaceutically acceptable salt thereof is present in the pharmaceutical composition at 10,000 ppm or less, 5,000 ppm or less, 2,000 ppm or less, 1,000 ppm or less, 500 ppm or less, 400 ppm or less, 300 ppm or less, 250 ppm or less, 200 ppm or less, 125 ppm or less, less than 125 ppm, 100 ppm or less, 90 ppm or less, 80 ppm or less, 70 ppm or less, 65 ppm or less, 0.001 ppm or more, 0.01 ppm or more, 0.1 ppm or more, 1 ppm or more, 5 ppm or more, 10 ppm or more, 15 ppm or more, 20 ppm or more. Above, 30ppm or more, 40ppm or more, 50ppm or more, 0.001~2000ppm, 0.001~1500ppm, 0.001~1000ppm, 0.001~500ppm, 0.001~300ppm, 0.001~200ppm, 0.001~125ppm, 0.0 01~100ppm, 0.001~90ppm, 0.001~80ppm, 0.001~70ppm, 0.001~60ppm, 0.001~50ppm, 0.001~40ppm, 0.001~30ppm, 0.003~2000ppm, 0.003~1500ppm, 0 .003~1000ppm, 0.003~500ppm, 0.003~300ppm, 0.003~200ppm, 0.003~125ppm, 0.003~100ppm, 0.003~90ppm, 0.003~80ppm, 0.003~70ppm, 0.003~60 ppm, 0.003~50ppm, 0.003~40ppm, 0.003~30ppm, 0.01~2000ppm, 0.01~1500ppm, 0.01~1000ppm, 0.01~500ppm, 0.01~300ppm, 0.01~200ppm, 0.01~125 ppm, 0.01~100ppm, 0.01~90ppm, 0.01~80ppm, 0.01~70ppm, 0.01~60ppm, 0.01~50ppm, 0.01~40ppm, 0.01~30ppm, 0.1~2000ppm, 0.1~1500ppm, 0.1~10 00ppm, 0.1~500ppm, 0.1~300ppm, 0.1~200ppm, 0.1~125ppm, 0.1~100ppm, 0.1~90ppm, 0.1~80ppm, 0.1~70ppm, 0.1~60ppm, 0.1~50ppm, 0.1~40ppm, 0.1~30ppm, 1~2000ppm, 1~1500ppm, 1~1000ppm, 1~500ppm, 1~300ppm, 1~200ppm, 1~12 5ppm, 1~100ppm, 1~90ppm, 1~80ppm, 1~70ppm, 1~60ppm, 1~50ppm, 1~40ppm, 1~30ppm, 3~2000ppm, 3~1500ppm, 3~1000ppm, 3~500ppm, 3~300ppm, 3~200ppm, 3~125ppm, 3~10 0ppm, 3~90ppm, 3~80ppm, 3~70ppm, 3~60ppm, 3~50ppm, 3~40ppm, 3~30ppm, 5~2000ppm , 5 to 1500 ppm, 5 to 1000 ppm, 5 to 500 ppm, 5 to 300 ppm, 5 to 200 ppm, 5 to 125 ppm, 5 to 100 ppm, 5 to 90 ppm, 5 to 80 ppm, 5 to 70 ppm, 5 to 60 ppm, 5 to 50 ppm, 5 to 40 ppm, 5 to 30 ppm, 10 to 2000 ppm, 10 to 1500 ppm, 10 to 1000 ppm, 10 to 500 ppm, 10 to 300 ppm, 10 to 200 ppm, 10 to 125 ppm, 10 to 100 ppm, 10 to 90 ppm, 10 to 80 ppm, 10 to 70 ppm, 10 to 60 ppm, 10 to 50 ppm, 10 to 40 ppm or 10 to 30 ppm. .

[0068] In one example, the pharmaceutical composition can be administered to a subject via various routes. The administration can refer to providing a predetermined substance to an individual (patient) via any suitable method, and the administration route of the pharmaceutical composition can be oral and / or parenteral administration via any common route as long as it can reach the target tissue. For parenteral administration, topical application to the skin, intraperitoneal injection, intrarectal injection, subcutaneous injection, intravenous injection, intramuscular injection, and / or intrathoracic injection can be selected. Furthermore, the composition according to one example can be administered using any device capable of delivering an active ingredient to target cells.

[0069] In one example, the subject to which the composition or method is applied refers to an animal that has or may develop coccidiosis, and the animal may be a mammal including humans, horses, cows, mice, rats, dogs, cats, etc., a bird including poultry (e.g., breeding chickens, meat chickens, and / or laying hens), a fish, an amphibian, and / or a reptile, etc.

[0070] In one example, the animal to which the composition or method is applied may be one or more species selected from the group consisting of animals listed in Table 1, such as one or more species selected from the group consisting of humans, chickens, ducks, geese, turkeys, quails, pheasants, pigeons, parrots, cows, pigs, goats, sheep, horses, antelopes, oryx, monkeys, cats, dogs, mice, rats, rabbits, raccoon dogs, squirrels, bats, guinea pigs, camels, lizards, alpacas, wombats, lizards, goldfish, crucian carp, tilapia, barbels, lungfish, and European chub. In one example, the animal may be an animal other than a human.

[0071] Another aspect provides an antiprotozoal composition against Eimeria protozoa comprising quinic acid and / or a salt thereof.

[0072] Another aspect provides the use of quinic acid and / or a salt thereof for the preparation of an antiprotozoal composition against Eimeria protozoa.

[0073] Another aspect provides a method for controlling Eimeria protozoa, comprising administering quinic acid and / or a salt thereof to a subject in need thereof.

[0074] The effects against quinic acid and Eimeria protozoa are as described above.

[0075] The antiprotozoan composition may further contain any suitable excipient or solvent, such as water, that is commonly used in antiprotozoan compositions, and such excipients may be, for example, preservatives, wetting agents, dispersing agents, suspending agents, buffers, stabilizers, or isotonic agents, but are not limited thereto.

[0076] In one example, the superior antiprotozoal activity (effect, efficacy) against Eimeria protozoa may refer to the following characteristics (1) and / or (2), and may, for example, exhibit the following characteristics (1) and / or (2) compared to a control group (a negative control group and / or a positive control group): (1) have high efficacy in killing Eimeria protozoa; and / or (2) Inhibiting the cell penetration effect of Eimeria protozoa and / or the proliferation effect of said protozoa within cells.

[0077] In one example, the quinic acid or a salt thereof may be included in the antiprotozoal composition in the same concentration ranges as those previously described for the feed composition and / or pharmaceutical composition.

[0078] Another aspect provides a feed additive comprising the antiprotozoal composition against Eimeria protozoa.

[0079] Another aspect provides a feed comprising the feed additive.

[0080] The feed may be prepared by mixing the anti-protozoan composition with the feed, or by adding the composition directly to the feed during the preparation of the feed.

[0081] The antiprotozoan composition in the feed may be in a liquid or dry state, for example, in the form of a dried powder. The antiprotozoan composition may be present in an amount of, but is not limited to, 0.005 to 10 wt%, 0.05 to 10 wt%, 0.1 to 10 wt%, 0.005 to 5 wt%, 0.05 to 5 wt%, 0.1 to 5 wt%, 0.005 to 2 wt%, 0.05 to 2 wt%, or 0.1 to 2 wt% of the total weight of the feed. In addition to the antiprotozoan composition, the feed may further contain conventional additives that can improve the shelf life of the feed.

[0082] In the present specification, the feed to which the anti-protozoan composition can be added may be selected from the group consisting of commercially available feed, grains, roots and fruits, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, cucumbers, grain by-products, proteins, inorganic substances, oils and fats, minerals, single-cell proteins, zooplankton, leftover food and drink, etc., but is not limited thereto.

[0083] Another example provides a food additive or drinking water additive containing the antiprotozoan composition as an active ingredient. By adding the antiprotozoan composition to drinking water, the number of Eimeria protozoa in the drinking water can be reduced. The Eimeria protozoa are as described above.

[0084] Another aspect provides a disinfectant comprising the antiprotozoal composition.

[0085] In another aspect, there is provided a disinfection method comprising applying the antiprotozoan composition to an object requiring disinfection. The disinfectant is a general term for preparations capable of controlling Eimeria protozoa, and can be used as a disinfectant for general household use, a disinfectant for food and cooking areas and facilities, and a disinfectant for buildings such as poultry farms and livestock barns, as well as various growing items such as stalks, drainage water, straw, egg shells, transport vehicles, and tableware.

[0086] Another aspect provides a cleaning agent comprising the antiprotozoal composition.

[0087] Another aspect provides a method of cleansing, comprising applying the antiprotozoal composition to a subject in need of cleansing from Eimeria protozoa.

[0088] Since the anti-protozoan composition has a killing effect on Eimeria protozoa, it can be used to cleanse the skin surface or various parts of the body of an individual that has been exposed to or may be exposed to Eimeria protozoa. [Effects of the Invention]

[0089] The present application relates to a composition for preventing, ameliorating or treating coccidiosis, which contains quinic acid, and a composition for antiprotozoal treatment against Eimeria protozoa, which has excellent killing effect against Eimeria protozoa. [Brief explanation of the drawings]

[0090] [Figure 1] A graph was also presented showing the results of treating Eimeria tenella protozoa with various concentrations of quinic acid and measuring the mortality rate of the protozoa. DETAILED DESCRIPTION OF THE INVENTION

[0091] The present invention will be described in more detail with reference to the following examples, which are merely for illustrative purposes and are not intended to limit the scope of the present invention.

[0092] Example 1. Direct killing effect on Eimeria protozoa A fixed amount of Eimeria tenella and Eimeria maxima oocysts (Gyeongsang National University, College of Water and Medicine, Republic of Korea) was placed in a tube filled with glass beads and crushed. To remove the oocyst cell walls and other debris, the inner sporangia were purified using Percoll density gradient and washed with PBS. To excyst the inner sporangia, Eimeria tenella and Eimeria maxima sporangia were treated with a reagent containing sodium taurocholic acid (Sigma Aldirich, USA) and trypsin (Ginco, USA), respectively, and incubated. After incubation, the parasites were washed once with phosphate-buffered saline (PBS).

[0093] Example 1-1. Direct killing effect of quinic acid on protozoa at different concentrations Quinic acid (Sigma, Cas No. 77-95-2) was incubated with Eimeria tenella larvae at concentrations ranging from 0 to 1000 ppm at 40°C for 3 hours, and live protozoa (sporozoites) were counted under a microscope. The mortality rate (%) of protozoa treated with each substance was measured relative to the negative control group treated with PBS. The results are shown in Figure 1 and Table 2, confirming the anticoxidial effect of quinic acid depending on the concentration.

[0094] [Table 2]

[0095] Example 1-2. Comparison of efficacy between chlorogenic acid components The killing effects of quinic acid (sigma, Cas No. 77-95-2), chlorogenic acid (sigma, Cas No. 327-97-9), m-coumaric acid (sigma, Cas No. 14755-02-3), caffeic acid (sigma, Cas No. 331-39-5), and ferulic acid (sigma, Cas No. 1135-24-6) on Eimeria protozoa were confirmed.

[0096] Eimeria tenella larvae and Eimeria maxima larvae were incubated with 0.1% (v / v) DMSO, quinic acid, chlorogenic acid, m-coumaric acid, caffeic acid, and ferulic acid at 10 ppm each for 3 hours at 40°C, and live protozoa (sporozoites) were counted under a microscope. The mortality rate (%) of larvae treated with each substance was measured relative to the negative control group treated with PBS, and the results are shown in Table 3 below.

[0097] [Table 3]

[0098] As shown in Table 3 above, at the same concentration (10 ppm), quinic acid exhibited superior direct killing effect against Eimeria tenella and Eimeria maxima protozoa than chlorogenic acid, m-coumaric acid, caffeic acid, and ferulic acid.

[0099] In addition, each material was treated up to a concentration of 1000 ppm to kill the Eimeria tenella protozoa, and the minimum treatment concentration for each material that showed a mortality rate of 50% or more against the Eimeria tenella protozoa is shown in Table 4 below.

[0100] [Table 4]

[0101] As shown in Table 4, the minimum concentration of quinic acid showing a mortality rate of 50% or more against Eimeria tenella protozoa was lower than that of chlorogenic acid, m-coumaric acid, caffeic acid, and ferulic acid, confirming that quinic acid has a significantly superior killing effect against Eimeria tenella protozoa.

[0102] Examples 1-3. Comparison of efficacy among chlorogenic acid family members The killing effects of quinic acid (sigma, Cas No. 77-95-2), chlorogenic acid (sigma, Cas No. 327-97-9), theogallin (3-galloylquinic acid, sigma, Cas No. 17365-11-6), and cryptochlorogenic acid (sigma, Cas No. 905-99-7) on Eimeria protozoa were confirmed.

[0103] Eimeria tenella protozoa were incubated with 0.1% (v / v) DMSO, quinic acid, chlorogenic acid, theogallin, and cryptogluconic acid at 10 ppm each for 3 hours at 40°C, and live protozoa (sporozoites) were counted under a microscope. The mortality rate (%) of the protozoa treated with each substance was measured relative to the negative control group treated with PBS, and the results are shown in Table 5 below.

[0104] [Table 5]

[0105] As shown in Table 5 above, at the same concentration (10 ppm), quinic acid exhibited a superior direct killing effect against Eimeria tenella protozoa than chlorogenic acid, theogallin, and cryptoglucogenic acid.

[0106] Example 1-4. Comparison of efficacy with sugarcane extract The effectiveness of quinic acid and sugarcane extract in killing Eimeria protozoa was confirmed. Sugarcane from China, Vietnam, and Brazil was used, and the sugarcane extract was extracted using water, methanol, and an organic solvent (a 3:1:1 volumetric mixture of methanol:water:chloroform).

[0107] Quinic acid or sugarcane extract was applied up to a concentration of 1000 ppm to kill Eimeria tenella protozoa, and the minimum treatment concentration showing a mortality rate of 50% or more against Eimeria tenella protozoa is shown in Table 6 below.

[0108] [Table 6]

[0109] As shown in Table 6, sugarcane extracts obtained from various origins and extraction methods did not exhibit any killing effect against Eimeria tenella protozoa even at concentrations up to 1000 ppm, confirming that quinic acid has a significantly superior killing effect against Eimeria tenella protozoa.

[0110] From the above description, those skilled in the art to which the present invention pertains will understand that the present invention can be embodied in other specific forms without changing the technical spirit or essential characteristics thereof. In this regard, it should be understood that the above-described embodiments are illustrative in all respects and are not limiting. The scope of the present invention should be interpreted as including all modifications and variations derived from the meaning and scope of the claims below, rather than the detailed description, and equivalent concepts.

Claims

1. A feed composition for preventing or ameliorating coccidiosis, comprising quinic acid or a salt thereof as an active ingredient.

2. 2. The feed composition of claim 1, wherein the coccidiosis is induced by the protozoan Eimeria sp.

3. 3. The feed composition according to claim 2, wherein the Eimeria protozoan is Eimeria tenella or Eimeria maxima.

4. The feed composition according to claim 1, wherein the feed composition contains the active ingredient at a concentration of 1% (w / w) or less based on the total weight of the feed.

5. The feed composition according to any one of claims 1 to 4, which is a feed additive.

6. A pharmaceutical composition for preventing or treating coccidiosis, comprising quinic acid or a salt thereof as an active ingredient.

7. 7. The pharmaceutical composition of claim 6, wherein the coccidiosis is induced by Eimeria sp. protozoa.

8. 8. The pharmaceutical composition according to claim 7, wherein the Eimeria protozoan is Eimeria tenella or Eimeria maxima.

9. A composition for use against protozoan parasites of the genus Eimeria, comprising quinic acid or a salt thereof as an active ingredient.

10. The composition for antiprotozoan infection according to claim 9, wherein the Eimeria protozoan is Eimeria tenella or Eimeria maxima.

11. 11. The feed additive according to claim 9 or claim 10, comprising an antiprotozoan composition.

12. 11. The disinfectant of claim 9 or claim 10, comprising an antiprotozoan composition.

13. 11. The cleaning agent of claim 9 or claim 10, comprising an antiprotozoan composition.

14. A method for preventing, ameliorating, or treating coccidiosis, comprising the step of administering to an animal, excluding humans, a composition selected from the group consisting of the feed composition according to any one of claims 1 to 4, the pharmaceutical composition according to any one of claims 6 to 8, and the composition for antiprotozoan diseases according to claim 9 or 10.

Images